Home Featured Page 296

Featured

Latest

UK Royal College of Psychiatrists Weighs In: Promise in Psychedelics, But Hype Mustn’t Outpace Evidence

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Ayahuasca’s Role in the Entourage Effect and Depression

MindMed Closes Upsized Financing of CAD $92.1m (USD $72.7m) to Meet...

MindMed Files Final Prospectus In Connection With Bought Deal Equity Financing

MindMed Files Preliminary Prospectus In Connection With Bought Deal Equity Financing

MindMed Upsizes Previously Announced Bought Deal Public Offering

MindMed Announces $50 Million Bought Deal Public Offering

MindMed Announces Successful Completion of Pre-IND Meeting with the FDA for...

MindMed Streamlines Leadership with Further Emphasis on Integrating Psychedelic Drug Development...

MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA...

MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical...

1...295296297 Page 296 of 297

UK Royal College of Psychiatrists Weighs In: Promise in Psychedelics, But...

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

UK Royal College of Psychiatrists Weighs In: Promise in Psychedelics, But Hype Mustn’t Outpace Evidence

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Ayahuasca’s Role in the Entourage Effect and Depression

MindMed Closes Upsized Financing of CAD $92.1m (USD $72.7m) to Meet...

MindMed Files Final Prospectus In Connection With Bought Deal Equity Financing

MindMed Files Preliminary Prospectus In Connection With Bought Deal Equity Financing

MindMed Upsizes Previously Announced Bought Deal Public Offering

MindMed Announces $50 Million Bought Deal Public Offering

MindMed Announces Successful Completion of Pre-IND Meeting with the FDA for...

MindMed Streamlines Leadership with Further Emphasis on Integrating Psychedelic Drug Development...

MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA...

MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical...

EDITOR PICKS

UK Royal College of Psychiatrists Weighs In: Promise in Psychedelics, But...

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY